



PRP ADVISORY

Presence of Bromofentanyl with etizolam/flubromazepam/caffeine detected in recent North Battleford police seizure

November 9, 2022

IMPORTANT

The CPSS has been notified by *Health Canada's* Drug Analysis Service that an analogue of fentanyl, namely **Bromofentanyl** (N-bromophenyl)-N-[1-(phenylethyl)-4-piperidinyl]-propanamide) CDSA Schedule I, Item 16 was present in a brown powder and/or grainy substance.

Other co-occurring substances were: **Fentanyl** (N-(1-phenethyl-4-piperidyl) propionanilide) **para-Fluorofentanyl** (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide), benzodiazepines, namely **Etizolam** (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine) and **Flubromazepam** (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) and **Caffeine**

The substance was received in *Health Canada* laboratory on October 31, 2022 and is the first detection of this substance of concern in the North Battleford area.

- The substance may also represent a threat to anyone handling it without taking the appropriate health and safety precautions.
- The Drug Analysis Service has instituted a policy to communicate advisories to clients as well as provincial and territorial public health authorities regarding potentially problematic substances. This policy aims to provide information, as part of an early warning system, to warn Canadians of new substances which may pose a potential health hazard.

QUESTIONS:

For more information, write to the **Prescription Review Program** at prp@cps.sk.ca or call 1-306-244-7355.